Longitudinal sampling is required to maximize detection of intrahost A/H3N2 virus variants. Issue 2 (1st December 2020)

• Record Type: Journal Article
• Authors: Koel, B F; Vigeveno, R M; Pater, M; Koekkoek, S M; Han, A X; Tuan, H M; Anh, T T N; Hung, N T; Thinh, L Q; Hai, L T; Ngoc, H T B; Chau, N V V; Ngoc, N M; Chokephaibulkit, K; Puthavathana, P; Kinh, N V; Trinh, T; Lee, R T C; Maurer-Stroh, S; Eggink, D; Thanh, T T; Tan, L V; van Doorn, H R; de Jong, M D
• Is Part Of: Virus evolution. Volume 6:Issue 2(2020)
• Publication Date: 2020-12-01
• Subjects: influenza virus -- within-host evolution -- next-generation sequencing; Viruses -- Evolution -- Periodicals; 579.2138
• DOI: 10.1093/ve/veaa088
• Languages: English
• ISSNs: 2057-1577

Abstract

Abstract: Seasonal human influenza viruses continually change antigenically to escape from neutralizing antibodies. It remains unclear how genetic variation in the intrahost virus population and selection at the level of individual hosts translates to the fast-paced evolution observed at the global level because emerging intrahost antigenic variants are rarely detected. We tracked intrahost variants in the hemagglutinin and neuraminidase surface proteins using longitudinally collected samples from 52 patients infected by A/H3N2 influenza virus, mostly young children, who received oseltamivir treatment. We identified emerging putative antigenic variants and oseltamivir-resistant variants, most of which remained detectable in samples collected at subsequent days, and identified variants that emerged intrahost immediately prior to increases in global rates. In contrast to most putative antigenic variants, oseltamivir-resistant variants rapidly increased to high frequencies in the virus population. Importantly, the majority of putative antigenic variants and oseltamivir-resistant variants were first detectable four or more days after onset of symptoms or start of treatment, respectively. Our observations demonstrate that de novo variants emerge, and may be positively selected, during the course of infection. Additionally, based on the 4–7 days post-treatment delay in emergence of oseltamivir-resistant variants in six out of the eight individuals with such variants, we find that limiting sample collection for routine surveillance and diagnostic testing to early timepoints after onset of symptoms can potentially preclude detection of emerging, positively selected variants.